Medicinova, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for MNOV, updated each market day.
MNOV AI Sentiment
AI sees no strong directional signal for Medicinova, Inc. stock over the next 10 market days.
Prediction date: June 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Medicinova, Inc.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
Sector
Exchange
Market Cap
$64,479,832
Cap Tier
Employees
6
Headquarters
LA JOLLA, CA
Listed Since
Dec. 7, 2006
Website
MNOV Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
MNOV Volatility
Medicinova, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
